Michael Behring
Overview
Explore the profile of Michael Behring including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients
Elkholy A, Avuthu N, Abdalla M, Behring M, Bajpai P, Kim H, et al.
Heliyon
. 2023 Jul;
9(7):e18035.
PMID: 37483698
Purpose: Although there is an established role for microbiome dysbiosis in the pathobiology of colorectal cancer (CRC), CRC patients of various race/ethnicities demonstrate distinct clinical behaviors. Thus, we investigated microbiome...
2.
Agarwal S, Afaq F, Bajpai P, Behring M, Kim H, Varambally A, et al.
Mol Cancer Res
. 2023 Apr;
21(7):698-712.
PMID: 37067340
Implications: FDA-approved small-molecule inhibitors of EZH2 can indirectly target BZW2 and because BZW2 functions as an oncogene, these inhibitors could serve as therapeutic agents for colorectal cancer.
3.
Patel C, Behring M, Al Diffalha S, Dhall D, Lee G, Shanmugam C, et al.
Cancer Med
. 2023 Mar;
12(8):9637-9643.
PMID: 36916704
Background: The prognostic value of mucinous adenocarcinomas (MCAs, exhibiting >50% extracellular mucin) of the colorectum, in relation to their anatomic location is not well studied. Materials And Methods: We compared...
4.
Dhall D, Makhoul E, Taguibao R, Waters K, Zhang W, Vail E, et al.
Hum Pathol
. 2023 Feb;
135:108-116.
PMID: 36754311
We studied pathogenic gene mutations and tumor mutation burden (TMB) in visible low-grade dysplastic lesions in patients with inflammatory bowel disease (IBD). The dysplastic lesions with histologically normal mucosa in...
5.
Obuya S, Elkholy A, Avuthu N, Behring M, Bajpai P, Agarwal S, et al.
J Gastrointest Oncol
. 2022 Nov;
13(5):2282-2292.
PMID: 36388691
Background: Colorectal cancer (CRC) is the fifth most diagnosed cancer in Sub-Saharan Africa. In Kenya, CRC incidence rates tripled from 1997 to 2017. In the Moi Teaching and Referral Hospital,...
6.
Behring M, Bajpai P, Afaq F, Elkholy A, Kim H, Al Diffalha S, et al.
J Pharm Pharmacol Res
. 2022 Oct;
6(3):147-157.
PMID: 36304424
Background: For several cancers, including those of the breast, young age at diagnosis is associated with an adverse prognosis. Although this effect is often attributed to heritable mutations such as...
7.
Shanmugam C, Behring M, Luthra V, Leal S, Varambally S, Netto G, et al.
BMJ Open
. 2022 Apr;
12(4):e053912.
PMID: 35450897
Background: Accurate detection of SARS-CoV-2 is necessary to mitigate the COVID-19 pandemic. However, the test reagents and assay platforms are varied and may not be sufficiently robust to diagnose COVID-19....
8.
Agarwal S, Afaq F, Bajpai P, Kim H, Elkholy A, Behring M, et al.
Mol Oncol
. 2022 Feb;
16(8):1728-1745.
PMID: 35194944
Thyroid receptor-interacting protein 13 (TRIP13), a protein of the AAA-ATPase family, is upregulated in various human cancers, including colorectal cancer (CRC). This study focused on the inhibition of TRIP13-induced CRC...
9.
Agarwal S, Behring M, Kim H, Bajpai P, Chakravarthi B, Gupta N, et al.
Transl Oncol
. 2021 Sep;
14(11):101142.
PMID: 34538338
No abstract available.
10.
Behring M, Ye Y, Elkholy A, Bajpai P, Agarwal S, Kim H, et al.
Cancer Med
. 2021 Jun;
10(16):5712-5720.
PMID: 34189853
Background: In silico deconvolution of invasive immune cell infiltration in bulk breast tumors helps characterize immunophenotype, expands treatment options, and influences survival endpoints. In this study, we identify the differential...